FORM 4
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden hours per response... 0.5

(Print or Type Responses)
1. Name and Address of Reporting Person *
ALTA BIOPHARMA PARTNERS II LP
   2. Issuer Name and Ticker or Trading Symbol
SCYNEXIS INC [SCYX] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director __X__ 10% Owner
_____ Officer (give title below) _____ Other (specify below)
(Last)
(First)
(Middle)
ONE EMBARCADERO CENTER, 37TH FLOOR		 3. Date of Earliest Transaction (Month/Day/Year)
05/07/2014
(Street)

SAN FRANCISCO, CA 94111		 4. If Amendment, Date Original Filed(Month/Day/Year)
 6. Individual or Joint/Group Filing(Check Applicable Line)
___ Form filed by One Reporting Person
_X_ Form filed by More than One Reporting Person
(City)
(State)
(Zip)
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)		 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code
(Instr. 8)		 4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)		 5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)		 6. Ownership Form: Direct (D) or Indirect (I)
(Instr. 4)		 7. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 05/07/2014   X   4,551 A $ 0.2 4,551 D (1)  
Common Stock 05/07/2014   X   4,551 A $ 0.2 9,102 D (1)  
Common Stock 05/07/2014   X   82,454 A $ 0.2 91,556 D (1)  
Common Stock 05/07/2014   C   161,238 A (3) 252,794 D (1)  
Common Stock 05/07/2014   C   50,239 A (4) 303,033 D (1)  
Common Stock 05/07/2014   C   69,476 A (4) 372,509 D (1)  
Common Stock 05/07/2014   P   868,066 A $ 10 1,240,575 D  
Common Stock 05/07/2014   X   174 A $ 0.2 174 I By Alta Embarcadero BioPharma Partners II, LLC (1) (2)
Common Stock 05/07/2014   X   174 A $ 0.2 348 I By Alta Embarcadero BioPharma Partners II, LLC (1) (2)
Common Stock 05/07/2014   X   3,033 A $ 0.2 3,381 I By Alta Embarcadero BioPharma Partners II, LLC (1) (2)
Common Stock 05/07/2014   C   5,931 A (3) 9,312 I By Alta Embarcadero BioPharma Partners II, LLC (1) (2)
Common Stock 05/07/2014   C   1,848 A (4) 11,160 I By Alta Embarcadero BioPharma Partners II, LLC (1) (2)
Common Stock 05/07/2014   C   2,642 A (5) 13,802 I By Alta Embarcadero BioPharma Partners II, LLC (1) (2)
Common Stock 05/07/2014   P   31,934 A $ 10 45,736 I By Alta Embarcadero BioPharma Partners II, LLC (1) (2)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 3)		 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code
(Instr. 8)		 5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4, and 5)		 6. Date Exercisable and Expiration Date
(Month/Day/Year)		 7. Title and Amount of Underlying Securities
(Instr. 3 and 4)		 8. Price of Derivative Security
(Instr. 5)		 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 4)		 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 4)		 11. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Common Stock Warrant (right to buy) $ 0.2 05/07/2014   X     4,551 12/07/2011 12/06/2016 Common Stock 4,551 $ 0 0 D (1)  
Common Stock Warrant (right to buy) $ 0.2 05/07/2014   X     4,551 05/15/2012 05/14/2017 Common Stock 4,551 $ 0 0 D (1)  
Common Stock Warrant (right to buy) $ 0.2 05/07/2014   X     82,454 12/11/2013 12/10/2018 Common Stock 82,454 $ 0 0 D (1)  
Series C Preferred Stock (3) 05/07/2014   C     570,159   (3)   (3) Common Stock 161,238 $ 0 0 D (1)  
Series D-1 Preferred Stock (4) 05/07/2014   C     1,024,876   (4)   (4) Common Stock 50,239 $ 0 0 D (1)  
Series D-2 Preferred Stock (5) 05/07/2014   C     1,417,315   (5)   (5) Common Stock 69,476 $ 0 0 D (1)  
Common Stock Warrant (right to buy) $ 0.2 05/07/2014   X     174 12/07/2011 12/06/2016 Common Stock 174 $ 0 0 I By Alta Embarcadero BioPharma Partners II, LLC (1) (2)
Common Stock Warrant (right to buy) $ 0.2 05/07/2014   X     174 05/15/2012 05/14/2017 Common Stock 174 $ 0 0 I By Alta Embarcadero BioPharma Partners II, LLC (1) (2)
Common Stock Warrant (right to buy) $ 0.2 05/07/2014   X     3,033 12/11/2013 12/10/2018 Common Stock 3,033 $ 0 0 I By Alta Embarcadero BioPharma Partners II, LLC (1) (2)
Series C Preferred Stock (3) 05/07/2014   C     20,975   (3)   (3) Common Stock 5,931 $ 0 0 I By Alta Embarcadero BioPharma Partners II, LLC (1) (2)
Series D-1 Preferred Stock (4) 05/07/2014   C     37,702   (4)   (4) Common Stock 1,848 $ 0 0 I By Alta Embarcadero BioPharma Partners II, LLC (1) (2)
Series D-2 Preferred Stock (5) 05/07/2014   C     53,915   (5)   (5) Common Stock 2,642 $ 0 0 I By Alta Embarcadero BioPharma Partners II, LLC (1) (2)

Reporting Owners

Reporting Owner Name / Address Relationships
 Director  10% Owner  Officer  Other
ALTA BIOPHARMA PARTNERS II LP
ONE EMBARCADERO CENTER, 37TH FLOOR
SAN FRANCISCO, CA 94111		     X    
ALTA BIOPHARMA MANAGEMENT II LLC
ONE EMBARCADERO CENTER, 37TH FLOOR
SAN FRANCISCO, CA 94111		     X    
ALTA EMBARCADERO BIOPHARMA PARTNERS II LLC
ONE EMBARCADERO CENTER, 37TH FLOOR
SAN FRANCISCO, CA 94111		     X    
CHAMPSI FARAH
ONE EMBARCADERO CENTER, 37TH FLOOR
SAN FRANCISCO, CA 94111		     X    

Signatures

 By: /s/ Farah Champsi, Managing Director   05/08/2014
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) Farah Champsi (known as the "Principal") is the managing director of Alta BioPharma Management II, LLC ("ABM II") (which is the general partner of Alta BioPharma Partners II, L.P. ("ABP II")), and manager of Alta Embarcadero BioPharma Partners II, LLC ("AEBP II"). As managing director and manager of such entities, Ms. Champsi may be deemed to have voting and investment power for the shares held by ABP II and AEBP II. The Principal disclaims beneficial ownership of all such shares held by ABP II and AEBP II, except to the extent of her proportionate pecuniary interests therein.
(2) These securities are held by AEBP II.
(3) Upon closing of the Issuer's initial public offering, each share of Series C Preferred Stock converted automatically into shares of common stock of the Issuer on a 1-for-3.536 basis, and had no expiration date.
(4) Upon closing of the Issuer's initial public offering, each share of Series D-1 Preferred Stock converted automatically into shares of common stock of the Issuer on a 1-for-20.4 basis, and had no expiration date.
(5) Upon closing of the Issuer's initial public offering, each share of Series D-2 Preferred Stock converted automatically into shares of common stock of the Issuer on a 1-for-20.4 basis, and had no expiration date.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.